In April 2020, the U.S. Food and Drug Administration (FDA) approved the prescription drug pemigatinib for the treatment of advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements. It should be used strictly in accordance with medical advice.

Mechanism of Action

FGFR2

Dosage and Administration

Route and frequency of administration of Pemigatinib: Oral, once daily.

Dosage adjustments for Pemigatinib should be made based on the patient's actual condition. For specific details, please consult your doctor and strictly follow medical advice.

Recommended Reading: Dosage and Administration of Pemigatinib

Side Effects

Common side effects: Alopecia (hair loss), diarrhea, dry eye syndrome.

Serious side effects: Ocular disorders, hyperphosphatemia.

Reference Article: Side Effects of Pemigatinib

Use in Specific Populations

Pregnancy: Pemigatinib may cause harm to a fetus or lead to miscarriage. You should not become pregnant while receiving treatment with Pemigatinib.

Lactation: It is unknown whether Pemigatinib passes into breast milk. Do not breastfeed during treatment and for 1 week after the last dose of Pemigatinib.

General Precautions

1. Follow all instructions on the prescription label and read all medication guides or leaflets. Take the medicine exactly as prescribed.

2. Take the medicine at the same time each day, with or without food.

3. Swallow the tablet whole. Do not crush, chew, split, or dissolve it.

from FDA，2022.08